Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Study protocol

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

Roman Hájek*, Richard Bryce, Sunhee Ro, Barbara Klencke and Heinz Ludwig

BMC Cancer 2012, 12:415  doi:10.1186/1471-2407-12-415

Article Metrics

3325
Total accesses

Article metric FAQ

Accesses  

  • Last 30 days: 83 accesses
  • Last 365 days: 1052 accesses
  • All time: 3325 accesses

These numbers are accesses on BioMed Central websites only, and an underestimate of total usage. More information